×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CAPR – capricor therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CAPR
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/11
09:00 am
capr
Capricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19
Low
Report
Capricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19
3/10
09:30 am
capr
FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment [Yahoo! Finance]
Low
Report
FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment [Yahoo! Finance]
3/10
09:13 am
capr
FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment
Medium
Report
FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment
3/7
10:42 am
capr
Capricor Therapeutics to Present at Leerink's Global Healthcare Conference 2025 [Yahoo! Finance]
Medium
Report
Capricor Therapeutics to Present at Leerink's Global Healthcare Conference 2025 [Yahoo! Finance]
3/7
09:25 am
capr
Capricor Therapeutics to Present at Leerink’s Global Healthcare Conference 2025
Medium
Report
Capricor Therapeutics to Present at Leerink’s Global Healthcare Conference 2025
3/4
12:28 pm
capr
Capricor Therapeutics Inc (NASDAQ: CAPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $77.00 price target on the stock.
Medium
Report
Capricor Therapeutics Inc (NASDAQ: CAPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $77.00 price target on the stock.
3/4
08:05 am
capr
Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy [Yahoo! Finance]
Medium
Report
Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy [Yahoo! Finance]
3/4
07:00 am
capr
Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy
Medium
Report
Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy
Date
Time
Symbol
Company Name
Action
%Chg
11/13/2024
04:01 pm
capr
capricor therapeutics, inc.
MISS
Report
10.7%
capricor therapeutics, inc.
8/7/2024
04:05 pm
capr
capricor therapeutics, inc.
MISS
Report
9.0%
capricor therapeutics, inc.
5/13/2024
04:05 pm
capr
capricor therapeutics, inc.
MISS
Report
-6.3%
capricor therapeutics, inc.
Date
Time
Symbol
Headline
Impact
3/5
05:00 pm
capr
Form 4 CAPRICOR THERAPEUTICS, For: Mar 03 Filed by: Marban Linda
Medium
Report
Form 4 CAPRICOR THERAPEUTICS, For: Mar 03 Filed by: Marban Linda
3/4
07:00 pm
capr
Form 4 CAPRICOR THERAPEUTICS, For: Mar 03 Filed by: Litvack Frank
Medium
Report
Form 4 CAPRICOR THERAPEUTICS, For: Mar 03 Filed by: Litvack Frank
3/4
07:00 pm
capr
Form 4 CAPRICOR THERAPEUTICS, For: Mar 03 Filed by: DUNBAR GEORGE W JR
Medium
Report
Form 4 CAPRICOR THERAPEUTICS, For: Mar 03 Filed by: DUNBAR GEORGE W JR
3/4
07:00 pm
capr
Form 4 CAPRICOR THERAPEUTICS, For: Mar 03 Filed by: Bergmann Anthony
Medium
Report
Form 4 CAPRICOR THERAPEUTICS, For: Mar 03 Filed by: Bergmann Anthony
3/4
07:05 am
capr
Form 8-K CAPRICOR THERAPEUTICS, For: Mar 04
Medium
Report
Form 8-K CAPRICOR THERAPEUTICS, For: Mar 04
2/28
07:30 pm
capr
Form 4 CAPRICOR THERAPEUTICS, For: Feb 27 Filed by: COLLIER EARL M JR
High
Report
Form 4 CAPRICOR THERAPEUTICS, For: Feb 27 Filed by: COLLIER EARL M JR
2/5
05:29 pm
capr
Form SCHEDULE 13G/A CAPRICOR THERAPEUTICS, Filed by: BlackRock, Inc.
Low
Report
Form SCHEDULE 13G/A CAPRICOR THERAPEUTICS, Filed by: BlackRock, Inc.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/29
New Capricor Data Reports 100 Percent Survival in Critical COVID-19 Patients Treated with CAP-1002
251.2%
7/15 Capricor Therapeutics Announces Positive Results from its Interim Analysis in the HOPE-2 Trial to Treat Patients with Duchenne Muscular Dystrophy 94.1%
3/24 Capricor Therapeutics to Host a Key Opinion Leader Call On Why Exosomes are Uniquely Suited for Vaccine Development 49.2%
3/24 Capricor Therapeutics Inc (NASDAQ: CAPR) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. 21.7%
9/17 Capricor Therapeutics (CAPR) Presents At 21st Annual H.C. Wainwright Global Investment Conference - Slideshow [Seeking Alpha] 19.3%
3/17 Capricor Therapeutics Announces Strategic Plan for Exosome Platform Technology Products Expansion 15.8%
4/30 Capricor Therapeutics Inc (NASDAQ: CAPR) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 12.0%
9/6 Capricor Therapeutics to Present at Upcoming Conferences 10.3%
10/15 Capricor Therapeutics Inc (NASDAQ: CAPR) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 10.1%
12/27 Form SC 13G CAPRICOR THERAPEUTICS, Filed by: ARMISTICE CAPITAL, LLC 9.5%
7/15 Capricor Therapeutics Announces Positive Results from its Interim Analysis in the HOPE-2 Trial to Treat Patients with Duchenne Muscular Dystrophy 94.1%
3/24 Capricor Therapeutics to Host a Key Opinion Leader Call On Why Exosomes are Uniquely Suited for Vaccine Development 49.2%
3/24 Capricor Therapeutics Inc (NASDAQ: CAPR) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. 21.7%
9/17 Capricor Therapeutics (CAPR) Presents At 21st Annual H.C. Wainwright Global Investment Conference - Slideshow [Seeking Alpha] 19.3%
3/17 Capricor Therapeutics Announces Strategic Plan for Exosome Platform Technology Products Expansion 15.8%
4/30 Capricor Therapeutics Inc (NASDAQ: CAPR) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 12.0%
9/6 Capricor Therapeutics to Present at Upcoming Conferences 10.3%
10/15 Capricor Therapeutics Inc (NASDAQ: CAPR) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 10.1%
12/27 Form SC 13G CAPRICOR THERAPEUTICS, Filed by: ARMISTICE CAPITAL, LLC 9.5%
TOP News Decliners
4/3
Capricor Initiates Compassionate Use Program for Severe COVID-19 Patients using CAP-1002, its Novel Cell Therapy
-37.5%
7/15 Capricor Therapeutics Inc (NASDAQ: CAPR) had its price target raised by analysts at HC Wainwright from $3.50 to $12.40. They now have a "buy" rating on the stock. -22.1%
7/25 Capricor Therapeutics Announces Positive DSMB Safety and Futility Review and Continuation of its HOPE-2 Study in Duchenne Muscular Dystrophy -16.6%
12/13 Form S-1/A CAPRICOR THERAPEUTICS, -16.0%
10/7 Capricor Presents Additional Positive Data from Ongoing HOPE-2 Study of CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society: Data Demonstrates Improved PUL 2.0 Performance at 6 Months -15.9%
7/22 Form 8-K CAPRICOR THERAPEUTICS, For: Jul 22 -13.0%
11/7 Q3/2019 9/30/2019 EPS -0.430 ZacksConsensus -0.700 ActVsEst 0.270 - Beat -12.4%
12/13 Form S-1/A CAPRICOR THERAPEUTICS, -11.9%
7/16 Capricor Therapeutics Inc (NASDAQ: CAPR) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -10.9%
7/17 Form S-3/A CAPRICOR THERAPEUTICS, -10.7%
7/15 Capricor Therapeutics Inc (NASDAQ: CAPR) had its price target raised by analysts at HC Wainwright from $3.50 to $12.40. They now have a "buy" rating on the stock. -22.1%
7/25 Capricor Therapeutics Announces Positive DSMB Safety and Futility Review and Continuation of its HOPE-2 Study in Duchenne Muscular Dystrophy -16.6%
12/13 Form S-1/A CAPRICOR THERAPEUTICS, -16.0%
10/7 Capricor Presents Additional Positive Data from Ongoing HOPE-2 Study of CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society: Data Demonstrates Improved PUL 2.0 Performance at 6 Months -15.9%
7/22 Form 8-K CAPRICOR THERAPEUTICS, For: Jul 22 -13.0%
11/7 Q3/2019 9/30/2019 EPS -0.430 ZacksConsensus -0.700 ActVsEst 0.270 - Beat -12.4%
12/13 Form S-1/A CAPRICOR THERAPEUTICS, -11.9%
7/16 Capricor Therapeutics Inc (NASDAQ: CAPR) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -10.9%
7/17 Form S-3/A CAPRICOR THERAPEUTICS, -10.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: